Dissecting the Heterogeneity of Treatment Response in First-Episode Schizophrenia

Schizophrenia Bulletin

Volumn 41, Issue 6, 2015, Pages 1224-1226

  Malhotra, Anil K ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Antipsychotic; Biomarkers; Cognition; Efficacy; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; RISPERIDONE; BIOLOGICAL MARKER; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AKATHISIA; APPLIED RESEARCH; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; GENETIC ASSOCIATION; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NEUROIMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SMOKING; TREATMENT RESPONSE; DRUG EFFECTS; FOLLOW UP; FRONTAL LOBE; NEOSTRIATUM; NERVE CELL NETWORK; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIOMARKERS; FOLLOW-UP STUDIES; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOSTRIATUM; NERVE NET; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84946126276     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv117     Document Type: Article

References (14)

1. Giordano SH, Temin S, Kirshner JJ, et al.; American Society of Clinical Oncology. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:2078-2099.
2. Yancy CW, Jessup M, Bozkurt B, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240-327.
3. Szeszko PR, Robinson DG, Ikuta T, et al. White matter changes associated with antipsychotic treatment in first-episode psychosis. Neuropsychopharmacology. 2014;39:1324-1331.
4. Argyelan M, Gallego J, Robinson D, et al. Abnormal resting state fMRI activity predicts processing speed deficits in first-episode psychosis. Neuropsychopharmacology. 2015;40:1631-1639.
5. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene are associated with severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012;69:904-912.
6. Sarpal DK, Argyelan M, Robinson DG, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry. In Press.
7. Sarpal D, Robinson D, Lencz T, et al. Antipsychotic treatment and functional connectivity of striatum: a prospective controlled study in first episode schizophrenia. JAMA Psychiatry. 2015;72:5-13.
8. Anticevic A, Hu X, Xiao Y, et al. Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change. J Neurosci. 2015;35:267-286.
9. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31:5-19.
10. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvements after treatment with second generation antipsychotic medications in first episode schizophrenia: is it a practice effect. Arch Gen Psychiatry. 2007;64:1115-1122.
11. Keefe RS, Bilder RM, Davis SM, et al.; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64:633-647.
12. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation predicts sustained response to antipsychotic medication in first episode schizophrenia. Am J Psychiatry. 2006;163:529-531.
13. Zhang J, Lencz T, Malhotra AK. Dopamine D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167:763-772.
14. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophreniaassociated genetic loci. Nature. 2014;511:421-427.